Barbara Beckerman's Page

Weekly remarks: GOP warns of new Obama taxes; Obama says reforms needed to ... - Los Angeles Times

Boston Globe

Weekly remarks: GOP warns of new Obama taxes; Obama says reforms needed to ... Los Angeles Times President Obama told the American people that his last $787 billion 'jobs bill,' the so-called 'stimulus' package, would ensure that unemployment would not ... GOP gives thanks, trashes Obama In First Thanksgiving Message, Obama Assures A Stronger Economy Next Holiday US health plan not everyone's cup of tea  -

Government involved with health reform? Why not? - NewsOK.com

Government involved with health reform? Why not? NewsOK.com ... though, should be the potential for greater government involvement in the health care system. As we have seen with the $787 billion "stimulus” bill, ...

Conflict of interest exists between AARP, reform - Bowling Green Daily News

CBC.ca

Conflict of interest exists between AARP, reform Bowling Green Daily News Our government gave a $18 million stimulus to AARP. Of course, the United Health Care Insurance Co. pays fees to AARP and its affiliates to promote its ... An Unhealthy Government Track Record Middle class is getting stuck again Big Government the Wrong Answer on Health Care  - -

Virdante Pharmaceuticals, Inc.: Series A $30M

Virdante Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on increasing potency of plasma-derived intravenous immune globulin for the treatment of inflammation and autoimmune disease, closed a $30M Series A financing. Participants include Thomas, McNerney & Partners, Osage Partners, Clarus Ventures, Venrock, MedImmune Ventures and Biogen Idec New Ventures.

Quinnova Pharmaceuticals, Inc.: Series B $17.4M

Quinnova Pharmaceuticals (Newtown, PA) a commercial-stage specialty biopharma company focused on dermatological drug reformulations and foam delivery systems, closed a $17.4M Series B financing. Participants include Safeguard Scientifics, Thomas, McNerney & Partners, H.I.G. Ventures.

Activaero, GmbH: Series A $15.9M

Activaero (Germany) a commercial-stage medical device company focused on patient-tailored controlled breathing and inhaled therapeutic delivery systems, closed a $15.9M Series A financing. Participants include BioMedPartners, VI Partners, Abalis Finance and Vesalius Biocapital.

3Q09 OnBioVC | Trend Analysis Now Available

Hot off the press! The 3Q09 OnBioVC | Trend Analysis study is now available for download [HERE]. Over $1,663M flowed into early-stage biopharma, diagnostic and device companies in the third quarter of 2009 and over $4,806M year-to-date! If you find the information in OnBioVC to be of value kindly forward on to colleagues who you [...]

September 2009 OnBioVC | Trend Analysis Now Available

Hot off the press! The September 2009 OnBioVC | Trend Analysis study is now available for download [HERE]. Over $465M flowed into early-stage biopharma, diagnostic and device companies in the ninth month of 2009 and over $4,806M year-to-date! If you find the information in OnBioVC to be of value kindly forward on to colleagues who [...]